Patents Represented by Attorney, Agent or Law Firm Julie K. Smith
-
Patent number: 7074408Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.Type: GrantFiled: February 23, 2001Date of Patent: July 11, 2006Assignee: Immunex CorporationInventors: William C. Fanslow, III, Douglas P. Cerretti, Kurt M. Poindexter, Roy A. Black
-
Patent number: 6824773Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2000Date of Patent: November 30, 2004Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 6727225Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: June 18, 2001Date of Patent: April 27, 2004Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 6642358Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.Type: GrantFiled: May 25, 2000Date of Patent: November 4, 2003Assignee: Immunex CorporationInventors: Charles Rauch, Henning Walczak
-
Patent number: 6569642Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.Type: GrantFiled: March 27, 2000Date of Patent: May 27, 2003Assignee: Immunex CorporationInventors: Charles Rauch, Henning Walczak
-
Patent number: 6548065Abstract: There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures.Type: GrantFiled: December 10, 1997Date of Patent: April 15, 2003Assignee: Immunex CorporationInventors: Dirk M. Anderson, Judith G. Giri
-
Patent number: 6541232Abstract: Purified and isolated IL-1/TNF-&agr;-activated kinase (ITAK), nucleic acids encoding ITAK, processes for production of recombinant forms of ITAK, pharmaceutical compositions containing ITAK, and use of ITAK in therapies and in various assays, including assays to detect antagonists and agonists of ITAK are provided.Type: GrantFiled: April 7, 2000Date of Patent: April 1, 2003Assignee: Immunex CorporationInventors: John E. Sims, G. Duke Virca, Timothy A. Bird, Dirk M. Anderson
-
Patent number: 6521424Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization. Also provided are materials and methods for recombinant expression of Tek antagonists.Type: GrantFiled: December 7, 2000Date of Patent: February 18, 2003Assignee: Immunex CorporationInventors: Douglas P. Cerretti, William C. Fanslow, III
-
Patent number: 6512095Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.Type: GrantFiled: February 6, 2001Date of Patent: January 28, 2003Assignee: Immunex Corp.Inventor: Peter R. Baum
-
Patent number: 6485956Abstract: The disclosure provides purified and isolated SVPH1-8 polypeptides, nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against such polypeptide, and fragmented peptides derived from these polypeptide. In addition, the disclosure provides uses of such polypeptides, fragmented peptides, antibodies and nucleic acids as well as kits containing the foregoing.Type: GrantFiled: July 14, 2000Date of Patent: November 26, 2002Assignee: Immunex CorporationInventor: Douglas P. Cerretti
-
Patent number: 6413932Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.Type: GrantFiled: June 7, 2000Date of Patent: July 2, 2002Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Luis G. Borges, William C. Farnslow, III
-
Patent number: 6184359Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: November 9, 1998Date of Patent: February 6, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 6177079Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the B- or &ggr;subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed. including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: November 20, 1998Date of Patent: January 23, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6168783Abstract: Antagonists of mammalian interleukin-15 (“IL-l5”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: August 14, 1998Date of Patent: January 2, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6165466Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: August 14, 1998Date of Patent: December 26, 2000Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6080557Abstract: Purified and isolated IL-1/TNF-.alpha.-activated kinase (ITAK), nucleic acids encoding ITAK, processes for production of recombinant forms of ITAK, pharmaceutical compositions containing ITAK, and use of ITAK in therapies and in various assays, including assays to detect antagonists and agonists of ITAK are provided.Type: GrantFiled: June 6, 1997Date of Patent: June 27, 2000Assignee: Immunex CorporationInventors: John E. Sims, G. Duke Virca, Timothy A. Bird, Dirk M. Anderson
-
Patent number: 6036978Abstract: The invention pertains to a controlled release pharmaceutical formulation that has an effective amount of a polypeptide selected from the group consisting of: (a) TNFR, (b) IL-1R, (c) IL-1ra, (d) IL-6R and (e) a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL-1; wherein the polypeptide is encapsulated in alginate. The invention also pertains to methods of treating inflammatory bowel disease by administering the above composition to a patient in need thereof.Type: GrantFiled: April 23, 1996Date of Patent: March 14, 2000Assignee: Immunex CorporationInventors: Wayne R. Gombotz, SiowFong Wee
-
Patent number: 6013480Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: August 14, 1998Date of Patent: January 11, 2000Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 5734013Abstract: A Steptomyces No. CBS 154.94 strain, mutants or derivatives thereof, and a method for preparing peptides using said strain, are disclosed. Novel peptides of general formula (1), pharmaceutical compositions containing same, and the use thereof in cancer therapy, are also disclosed.Type: GrantFiled: September 27, 1996Date of Patent: March 31, 1998Assignee: Rhone-Poulenc Rorer S.A.Inventors: Jean-Jacques Debernard, Thierry Flamant, Didier Van Der Pyl
-
Patent number: 5656595Abstract: The present invention relates to peptides capable of modulating the levels of GDP exchange on p21-GDP complexes, the nucleic acid sequences coding for said peptides, preparation thereof and pharmaceutical compositions containing them.Type: GrantFiled: October 19, 1994Date of Patent: August 12, 1997Assignee: Rhone-Poulenc Rorer S.A.Inventors: Fabien Schweighoffer, Bruno Tocque